In the pharma sector, Sandeep Bhatia, Managing Director and Head of Equity – India at Macquarie Capital flagged uncertainties related to US pricing pressures. Referring to Sun Pharma, he noted that the company, which gets about 20% of its revenue from innovative drugs in the US, had not received any notice from regulators yet. However, he cautioned, “With the Trump administration, everything is a work in progress… things can move suddenly in the other direction.”
